Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

3SBio obtains ex-China global rights to Apexigen's anti-TNF mAb technology

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it has acquired the ex-China global rights to Apexigen's anti-TNF monoclonal antibody ("mAb") technology. 3SBio previously acquired the China rights from Apexigen in 2006.

23 Jun 2015

ImmunoCellular, Pure MHC partner to develop new assay for ICT-107 phase 3 registrational clinical program

ImmunoCellular Therapeutics, Ltd. announced an agreement with Pure MHC, an Emergent Technologies portfolio company, for development of a novel assay for quality control that will be an important component of ImmunoCellular's ICT-107 phase 3 registrational clinical program in newly diagnosed glioblastoma, anticipated to begin in the second half of 2015.

22 Jun 2015

Hormones used in breast cancer treatment could affect disease progression, outcomes in some patients

Recently, researchers have discovered that the hormone progesterone, an ingredient in contraceptives and menopausal hormone replacement therapies, might stimulate the growth of breast cancer cells that are resistant to anti-estrogen therapy and chemotherapy.

22 Jun 2015

New multidisciplinary Centre For Research into Obesity and Related Diseases opens In Sao Paulo

Researchers, clinicians, health educators and policy makers all gathered on May 4th in Sao Paulo, Brazil, as the new Multidisciplinary Centre for Research into Obesity and Related Comorbidities (Cepid-OCRC) was opened at da Universidade Estadual de Campinas (UNICAMP).

From Bruker BioSpin Group 22 Jun 2015

PD linked to increased cancer risk in Asian population

A Taiwanese population-based cohort study reports an increased risk of most cancers in patients with Parkinson’s disease, contrasting with findings in Western populations.

19 Jun 2015

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

Eli Lilly and Company announced that The Lancet Oncology has published results of the Phase III REACH trial that evaluated CYRAMZA (ramucirumab) as a second-line treatment for people with hepatocellular carcinoma (HCC), also known as liver cancer. While the REACH trial's primary endpoint of overall survival favored the CYRAMZA arm, it was not statistically significant.

19 Jun 2015

UNC Lineberger scientists contribute to better understanding of genetic mutations in melanoma

UNC Lineberger Comprehensive Cancer Center researchers have significantly contributed to a better understanding of the genetic alterations found in cutaneous melanoma, the most lethal form of skin cancer, as part of a multi-institution, international effort of The Cancer Genome Atlas.

19 Jun 2015

Scientists identify four melanoma subtypes that share common 'downstream' signaling pathways

Cutaneous melanoma, the most deadly form of skin cancer, is now believed to be divided into four distinct genomic subtypes, say researchers at The University of Texas MD Anderson Cancer Center, a finding that could prove valuable in the ever-increasing pursuit of personalized medicine.

19 Jun 2015

Researchers track down key gene mutation responsible for causing acute lymphoblastic leukemia

Two medical researchers from the Children's Hospital of Michigan and the Wayne State University School of Medicine have published the results of a nearly 10-year investigation that identified a key gene mutation that can trigger acute lymphoblastic leukemia, or ALL, and several other types of cancer.

18 Jun 2015

Researchers highlight important factors that impact early-stage breast cancer patients' access to BCT

The first comprehensive national review of breast-conserving therapy (BCT) shows that over the last 13 years rates of this treatment modality for early-stage breast cancer have increased at a steady pace. However, the review also highlights important demographic factors that impact which patients have access to BCT.

18 Jun 2015

Johns Hopkins researchers develop new imaging technology to help remove brain tumors safely

Brain surgery is famously difficult for good reason: When removing a tumor, for example, neurosurgeons walk a tightrope as they try to take out as much of the cancer as possible while keeping crucial brain tissue intact — and visually distinguishing the two is often impossible.

18 Jun 2015

Bivalent HPV vaccine efficacy may be independent of dose

Fewer than three doses of the bivalent human papillomavirus vaccine may be sufficient to offer adequate protection against cervical HPV-16 and -18 infection, research published in The Lancet Oncology indicates.

17 Jun 2015

Lilly, Sarah Cannon Research Institute partner to co‑develop investigational oncology compound

Eli Lilly and Company and Sarah Cannon Research Institute today announced a strategic partnership to co‑develop an investigational oncology compound, LY3023414, a PI3K/mTOR dual inhibitor. Under the agreement, SCRI will collaborate with Lilly to provide clinical development expertise and program design, as well as medical oversight and trial management. Patient enrollment for the initial Phase II clinical trial is underway.

17 Jun 2015

New open access journal to deliver case reports on all aspects of pancreatic cancer

Case Reports in Pancreatic Cancer, a new peer-reviewed, open access journal from Mary Ann Liebert, Inc., publishers, will deliver authoritative case reports on all aspects of pancreatic cancer diagnosis, management, treatment, and outcomes.

17 Jun 2015

Loyola tests new combination treatment for people living with cancer that has spread to spine

Loyola University Medical Center is the first center in the country to enroll patients in a clinical trial of a minimally invasive treatment for patients living with cancer that has spread to the spine.

17 Jun 2015

Elekta's Esteya electronic brachytherapy improves outcomes in patients with basal cell carcinoma

Physicians at La Fe University and Polytechnic Hospital - Valencia presented their early clinical outcome data on the use of Esteya electronic brachytherapy for the treatment of basal cell carcinoma in a paper in the current issue of Journal of Contemporary Brachytherapy. The ongoing study showed 100 percent complete response and excellent cosmetic outcome in all lesions treated to date with Esteya.

From Elekta 17 Jun 2015

Young thyroid cancer patients with lymph node involvement at increased risk of dying

Patients older than age 45 with thyroid cancer that has spread to neck lymph nodes have long been considered at higher risk of dying, but the same has not been true for younger patients.

17 Jun 2015

Breakthrough discovery on element transformation could lead to new way for treating cancer with radiation

Chemists at Tufts University's School of Arts and Sciences, collaborating with PerkinElmer and UCL (University College London), have witnessed atoms of one chemical element morph into another for the first time ever -- a feat that produced an unexpected outcome that could lead to a new way to safely treat cancer with radiation.

17 Jun 2015

Experts review strategies that may help improve adoptive cell immunotherapy for treating cancer

In a special issue of Immunotherapy, leading experts provide in-depth review of innovative strategies that may further the success of adoptive cell immunotherapy as a cancer treatment. Adoptive cell immunotherapy (ACT) has proven successful in clinical trials against certain types of melanoma and leukemia. The journal reviews new strategies to address the challenges of extending these effects to a wider range of tumor types.

17 Jun 2015

CytomX closes $70 million Series D financing round

CytomX, a biotechnology company developing Probody™ therapeutics for the treatment of cancer, today announced the closing of a $70 million Series D financing round. The financing was led by Fidelity Management & Research Company with participation from Casdin Capital, Cormorant Asset Management, Deerfield Management, Perceptive Advisors, Redmile Group, Tekla Healthcare Investors and Tekla Life Sciences Investors, Venrock Healthcare Capital Partners, Wellington Management Company and additional undisclosed investors.

17 Jun 2015

Oncology News and Research

Further Reading

3SBio obtains ex-China global rights to Apexigen's anti-TNF mAb technology

ImmunoCellular, Pure MHC partner to develop new assay for ICT-107 phase 3 registrational clinical program

Hormones used in breast cancer treatment could affect disease progression, outcomes in some patients

New multidisciplinary Centre For Research into Obesity and Related Diseases opens In Sao Paulo

PD linked to increased cancer risk in Asian population

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

UNC Lineberger scientists contribute to better understanding of genetic mutations in melanoma

Scientists identify four melanoma subtypes that share common 'downstream' signaling pathways

Researchers track down key gene mutation responsible for causing acute lymphoblastic leukemia

Researchers highlight important factors that impact early-stage breast cancer patients' access to BCT

Johns Hopkins researchers develop new imaging technology to help remove brain tumors safely

Bivalent HPV vaccine efficacy may be independent of dose

Lilly, Sarah Cannon Research Institute partner to co‑develop investigational oncology compound

New open access journal to deliver case reports on all aspects of pancreatic cancer

Loyola tests new combination treatment for people living with cancer that has spread to spine

Elekta's Esteya electronic brachytherapy improves outcomes in patients with basal cell carcinoma

Young thyroid cancer patients with lymph node involvement at increased risk of dying

Breakthrough discovery on element transformation could lead to new way for treating cancer with radiation

Experts review strategies that may help improve adoptive cell immunotherapy for treating cancer

CytomX closes $70 million Series D financing round

eBook: Liquid biopsy in cancer research eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News